Updated Guideline for Hypertrophic Cardiomyopathy

New recommendations include exercise prescription and treatment with cardiac myosin inhibitors.

Sponsoring Organizations: American Heart Association (AHA) and American College of Cardiology (ACC); endorsed by the American Medical Society for Sports Medicine (AMSSM), the Heart Rhythm Society (HRS), and the Pediatric and Congenital Electrophysiology Society (PACES)

Target Audience: Primary care clinicians, cardiologists

Background and Objective

A working group reviewed evidence published since the 2020 guideline and updated recommendations for diagnosis and management of hypertrophic cardiomyopathy (HCM).

What's Changed

Exercise and cardiac myosin inhibitors are now recommended.

Key Points

Shared decision making is foremost in caring for patients with HCM, and indeed all patients. During the last 10 to 15 years, patient autonomy has replaced a…

Reviewing Author

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate